
|Videos|April 24, 2017
Biosimilars in Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses the potential impact of biosimilars on specialty pharmacy.
Advertisement
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses the potential impact of biosimilars on specialty pharmacy.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
2
From Type 1 to Type 2 and Beyond: Navigating the Landscape of Diabetes
3
Doxecitine–Doxribtimine Becomes First Approved Treatment for Rare Genetic Disorder
4
COVID-19 Reinfection Heightens Risk of Postacute Sequelae of SARS-CoV-2 in Pediatrics
5














































































































































































































